Please click on the hyperlinked title to open the slide presentation in PDF format of the conference speaker.

This will be updated as speakers submit their final presentation version to be uploaded.

This usually happens after the end of the conference but all efforts will be made to upload the presentation as quickly as possible after receiving the file.

ADDI 2018-Program

Monday, December 3, 2018:

Welcome Remarks: Albert P. Li, APSciences/IVAL

 

Session 1:  Pioneer Lectures:  Tools and Experimental Approaches for Assessment of Drug-drug Interactions (Chair:  Joan Zuo, The Chinese University, Hong Kong)

 

9:15 AM – 9:45 AM

Mechanisms and Clinical Significance of Hepatic Drug-drug Interactions Involving Efflux Drug Transporters (Kim Brouwer, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA) 

 

9:45 AM – 10:15 AM

Extrapolation of In Vitro Drug-drug Interaction Data to In Vivo Clinical Findings (Yuichi Sugiyama, RIKEN Baton Zone Program, RIKEN Cluster for Science, Technology and Innovation Hub, RIKEN; Yokohama, Japan)

 

10:45 AM – 11:15 AM

Novel Human In Vitro Hepatic and Enteric Experimental Systems for the Evaluation of Drug-drug Interactions (Albert P. Li, IVAL; Columbia, MD, USA)

 

 

Session 2: Clinical Evaluation Drug-drug Interactions (Chair:  Joan Zuo, WuXi AppTec)

 

1:45 PM – 2:15 PM

IND Preparation and Submission for Both Chinese CDA and USFDA (Zhuohan Hu, Research Institute for Liver Diseases (Shanghai) Co., Ltd.; Shanghai, China)

 

2:15 PM – 2:45 PM

Drug-Drug Interaction: Clinical Aspects (Sylvia Zhao, China Novartis Institutes of Biomedical Research, Shanghai, China)

 

2:45 PM – 3:15 PM

Mechanistic Analysis of the Risk of Pharmacokinetic Drug-drug Interactions with Drugs Recently Approved by the US Food and Drug Administration (Jingjing Yu, University of Washington; Seattle, WA, USA)

 

3:45 PM – 4:15 PM

Clinical Trial on DDI Risk Assessment – Case Studies (Min Huang, Sun Yat-sen University, Guangzhou, China)

 

4:15 PM – 4:45 PM

Translating the In Vitro DDI Properties into Human Drug-drug Interactions Using Physiologically based Pharmacokinetic Modeling (Jing Lin*, Sunovion Pharmaceuticals Inc; Marlborough, MA; Gerald R. Galluppi, Estela Skende, Yu-Luan Chen, Soujanya Sunkaraneni, Kaushik Sarma, Kenneth S. Koblan, Seth C. Hopkins) SPEAKER WILL SEND PDF COPY

 

 

Tuesday, December 4, 2018

 

Session 3: Transporter-mediated Drug-drug Interactions (Chair:  Yuichi Sugiyama, RIKEN Baton Zone Program, RIKEN Cluster for Science, Technology and Innovation Hub, RIKEN)

 

9:00 AM – 9:30 AM

The In Vitro Assays for Evaluating BSEP Inhibition Potencies of Drugs (Sumito Ito, Genomembrane, Kanagawa, Japan) 

 

9:30 AM – 10:00 AM

Predicting Complex DDIs Related to CYP Induction and OATP Inhibition by PBPK Model of Rifampicin with its own Hepatic Uptake and Auto-induction (Ryuta Asaumi, Ono Pharmaceutical, Ibaraki, Japan)

 

10:00 AM – 10:30 AM

Application of PBPK Modeling to Renal OCT2 and MATEs mediated DDIs: Predicting Changes in Renal Clearance and Blood AUC Caused by the Transporter Inhibitors (Kotaro Nishiyama, Nippon Boehringer Ingelheim, Kobe, Japan) 

 

11:00 AM – 11:30 AM

Quantitative Analysis of Complex Drug-drug Interactions using PBPK Models with In Vitro Inhibition Data: Repaglinide and Cerivastatin (Soo-Jin Kim, CJ HealthCare, Seoul, Republic of Korea)

 

11:30 AM – 12:00 PM

Factors Influencing Variability of In Vitro Parameters for P-glycoprotein / Breast Cancer Resistance Protein (Naoki Ishiguro, Nippon Boehringer Ingelheim, Kobe, Japan)

2:00 PM – 2:30 PM

Case Study on Rental Transporter Mediated DDI: Weak Interactions between Cimetidine and OCT2 Specific Substrate Fampridine (Guangqing Xiao, Takeda Pharmaceuticals International Co., Cambridge, MA, USA)

 

2:30 PM – 3:00 PM

Hepatocellular Disposition Profiling of Rosuvastatin and Pitavastatin in Sandwich-Cultured Human Hepatocytes: (Katsuhiro Kanda, Hitachi High-Technologies Corporation, Ibaraki, Japan)

 

 

Wednesday, December 5, 2018

 

Session 4: Drug Metabolizing Enzyme-mediated Drug-drug Interactions (Chair:  Chuang Lu, Sanofi)

 

9:00 AM – 9:30 AM

PBPK Modeling to Describe DDI in Intestine vs. Liver Drug Removal (K. Sandy Pang, University of Toronto, Toronto, Canada) SPEAKER CANNOT PUBLISH AT THIS TIME, PLEASE CONTACT SPEAKER DIRECTLY FOR COPY OF SLIDES WHEN AVAILABLE

 

9:30 AM – 10:00 AM

Use of Cluster Newton Method to Obtain Reliable In Vivo Ki Values by Analyzing the Change in Pharmacokinetics of both Parent and Metabolites of Victim Compound (Kazuya Maeda, The University of Tokyo, Tokyo, Japan)

 

10:00 AM – 10:30 AM

Assessment of CYP1A2 Inductive Potential of Edaravone, a New Drug Approved for ALS, and Necessity Judgment of the Clinical DDI Study (Norihiko Iwazaki, Mitsubishi-Tanabe Pharma Corporation, Saitama, Japan)

 

11:00 AM – 11:30 AM

Heterotropic Activation of CYP3A5 by Icotinib and the Enhancement Effect of Ketoconazole (Xiaomei Zhuang, Institute of Pharmacology and Toxicology, AMMS, Beijing, China)  

 

11:30 AM – 12:00 PM

Prediction of Time-dependent DDI with CYP3A in the Liver and Intestine Based on the PBPK Modeling and Comparison with Data from Clinical DDI Study (Toru Takenaka, Taiho Pharmaceutical Co., LTD., Tsukuba, Japan)

 

12:00 PM – 12:30 PM – PANEL DISSCUSSION SESSION 4

 

Session 5: Atypical Drug-drug Interactions (Chair:  Lilly Xu, Chem Partner)

 

2:00 PM – 2:30 PM

Target-mediated Drug Disposition in Small Molecule Drugs: Its Role in Atypical Pharmacokinetic Non-linearity and DDI

2:30 PM – 3:00 PM

Physiologically-based Pharmacokinetic Analysis of Nonlinear Pharmacokinetics of Paclitaxel and Drug Interactions with other Drugs 

 

3:00 PM – 3:30 PM

Recent Advances in Reaction Phenotyping to Access Victim Drug-Drug Interaction (Li Di, Pfizer Inc., Groton, CT, USA) 

 

 

4:00 PM – 4:30 PM

Application of In Vitro “Dissolution/permeation (D/P) System” to Predict Absorption-based Drug-drug Interaction

 

4:30 PM – 5:00 PM

HLA, CYP, and DDI; the SCAR Determinant and Contributing Factors (Chonlaphat Sukasem, Mahidol University; Ramathibodi Hospital, Bangkok, Thailand)  

 

5:00 PM – 5:30 PM

Interplays of Herbal Medicines with Gut Microbiota Contribute to their Disposition and Efficacy and Interactions with Conventional Medicines (Ru Yan, University of Macau, Taipa, Macao, China)

 

5:30 PM – 6:00 PM – PANEL DISCUSSION SESSION 5

 

 

Thursday. December 6, 2018

 

Session 6: Novel Technologies for the Evaluation of Drug-drug Interactions (Chair:  Albert P. Li, IVAL)

 

9:00 AM – 9:30 AM

Apply Primary Human Hepatocyte Enriched with Human Plasma in Various In Vitro DDI Assays (Chuang Lu, Sanofi, Cambridge, MA, USA)

 

9:30 AM – 10:00 AM

Integrating BSEP Inhibition and FXR Mediated Regulation of Bile Acids to Improve Prediction of Cholestatic Drug Induced Liver Injury. (Kenneth Brouwer, BioIVT, Durham, NC, USA)

10:00 AM – 10:30 AM

Case Study for Improvements of CYP DDI Victim Risk GAP between Perspective and Retrospective Prediction Using New ADME Tools, Chimeric Mice with Humanized Liver (Daisuke Tenmizu, Astellas Pharma Inc., Tsukuba, Japan)

 

11:00 AM – 11:30 AM

Drug-Vitamin Transporter Interaction: Is It Ripe for a Thiamine Transporter (THTR2) Decision Tree? (Yan Zhang, Incyte Corporation, Wilmington, DE, USA)

 

11:30 AM – 12:00 PM

Preclinical Evaluation of Drug-Drug Interaction Potential in Drug Discovery:  Challenging the Status Quo (Simon G. Wong, Genentech, South San Francisco, California, USA) 

 

12:00 PM – 12:30 PM – PANEL DISCUSSION SESSION 6

 

Session 7: Herb-drug Interactions (Chair:  Joan Zuo, CUHK)

 

2:00 PM – 2:30 PM

East meets West: Overview of Herb-drug Interaction Research in Hong Kong (Joan Zuo, CUHK, Hong Kong, China)

 

2:30 PM – 3:00 PM

A Pragmatic Approach to Review Herb-drug Interactions for Implementation of Integrative Medicine (Timothy Yung, Hospital Authority of Hong Kong, Hong Kong, China) 

 

3:00 PM – 3:30 PM

Beneficial Herb-drug Interaction in the Combinational Use of Herbal Polyoxypregnanes with Paclitaxel (Ge Lin, The Chinese University of Hong Kong, Hong Kong, China) 

 

 

4:00 PM – 4:30 PM

Schisandra Sphenanthera: its Herb-drug Interactions and Hepatoprotection (Huichang Bi, Sun Yat-sen University, Guangzhou, China)  

 

4:30 PM – 5:00 PM

Intravenous XueShuanTong: Human Pharmacokinetics of Ginsenosides and its Potential for CYP3A- and OATP1B-mediated Drug Interactions (Chuan Li, Chinese Academy of Science, Beijing, China) 

5:00 PM – 5:30 PM

Herb-drug Interactions – Do they Matter in the Clinic?  (Brian Tomlinson, The Chinese University of Hong Kong, Shatin, Hong Kong, China) 

 

5:30 PM – 6:00 PM – PANEL DISCUSSION SESSION 7

 

6:00 PM – 6:30 PM – Closing Remarks (Albert P. Li, IVAL)

 

END OF CONFERENCE